Targeting LIG1 with PARP Inhibitors: E New Target Identified Using CRISPR
/in CRISPR, PARPi, Preclinical Research/by MaxNew Nanoparticle Therapy Holds Promise for Prostate Cancer Patients
/in Delivery, Preclinical Research/by MaxRepurposing FDA-Approved Drugs for PIM-1 Kinase Inhibition: A Potential Avenue for Prostate Cancer
/in Drug repurposing, Preclinical Research/by MaxNew Hope for Neuroendocrine Prostate Cancer: Targeting Mitochondrial HSP60
/in Preclinical Research/by MaxCRISPR Gene Editing Silences Cancer-Causing Mutations
/in CRISPR, Not PCa related, Preclinical Research/by MaxDinuclear Platinum(II) Complexes: A Promising New Chemotherapy to Treating Prostate Cancer
/in Chemotherapy, Preclinical Research/by MaxHijacking the Brakes: Scientists Uncover Prostate Cancer’s Growth Secret
/in CRISPR, Preclinical Research/by MaxProject Navigator
Let's try to finance it!
A new, user friendly way, to get information about current clinical trials available to prostate cancer patients.
Tags
177Lu-PSMA-617 abiraterone abiraterone acetate ADC ADT ai in healthcare antibody-drug conjugate apalutamide ATM B7-H3 bispecific antibody bone metastases bone metastasis BRCA BRCA2 cancer immunotherapy CAR-T CD3 clinical trial crispr darolutamide docetaxel drug repurposing drug resistance enzalutamide EZH2 inhibitor HRR immunotherapy mcrpc mHSPC mRNA NEPC neuroendocrine prostate cancer oncolytic virus PARP1 PARP inhibitor Pluvicto prostate cancer protac PSMA radioligand therapy radiopharmaceuticals real-world data STEAP1 T-cell therapy
Latest Posts
- Newsletter 43/2026 October 25, 2026
- Phase 3 DASL-HiCaP: Darolutamide Reduces Metastasis Risk in High-Risk Prostate Cancer October 24, 2026
- UPDATE: PROTEUS Substudy Shows Improved Event-Free Survival With Perioperative Apalutamide October 24, 2026
- UPDATE: Bavdegalutamide Shows Stronger Activity in Prostate Cancers With Specific AR Mutations October 23, 2026